This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hall, J. E. Search for Related Content PubMed Articles by Hall, J. E. Related Collections Lipids

(Hypertension. 2002;39:189.)
© 2002 American Heart Association, Inc.

Hypertension Electronic Pages

Hypertension Online Only

January 2002

John E. Hall, Editor-in-Chief
The Scientific Publishing Committee has approved Hypertension to receive a limited number of electronic pages. These electronic pages will be used to help increase the number of referenceable pages for the journal by allowing us to publish Editorials, Letters to the Editors and their respective responses, Scientific Contributions, and other materials online. Thus, Hypertension Online material will be indexed in Index Medicus, MEDLINE, and PubMed. Each online item will also be featured in the Table of Contents on the cover, denoted by a green star, as well as in the Table of Contents within the journal, denoted by the letter e in front of the page number. Hypertension is available online at http://www.hypertensionaha.org

Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)

Comparison With Enalapril
Juerg Nussberger

Grégoire Wuerzner

Chris Jensen

Hans R. Brunner

Abstract—
Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by direct inhibition of renin. So far, specific renin inhibitors lacked potency and/or oral availability. We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol. In 3 periods of 8 days, separated by wash-outs of 6 days, each volunteer received 2 dosage levels of Aliskiren (low before high; 40 and 80 or 160 and 640 mg/d) and randomized placebo or 20 mg enalapril. Aliskiren was well tolerated. Not surprisingly, blood pressure and heart rate remained unchanged in . . . [Full Text of this Article]